A survival rate of 80% at one year was just one of the encouraging findings from Thoratec's (Pleasanton, California) ROADMAP (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients) study that supports the HeartMate II LVAD. However, some analysts say that the data will have no significant impact on adoption rates of the device. Read More
